Vol. 5 No. 2 (2026)

Pakistan Journal of Medical & Cardiological Review

https://pakjmcr.com/index.php/1/about

Online ISSN 3007-2387

Print ISSN 3007-2379

Molecular Mechanisms of Neurodegeneration: Role of Tau Protein Aggregation in Alzheimer's Disease Using Western Blot and Immunohistochemistry

Aisha Bibi (Corresponding Author)
Department of Biochemistry, University of Karachi. ayesha.ishaque786@gmail.com

Talha
University of Makran. talha@uomp.edu.pk

Author Details

Keywords: Tau protein; Alzheimer's disease; Neurodegeneration; Neurofibrillary tangles; Western blot; Immunohistochemistry; Protein aggregation; Hyperphosphorylation; Biomarkers; Neuroinflammation

Received on 4 May 2026

Accepted on 7 Jun 2026

Published on 12 Jun 2026

Corresponding E-mail & Author*:

Aisha Bibi
Department of Biochemistry, University of Karachi.
ayesha.ishaque786@gmail.com

Abstract

Neurodegenerative disorders, particularly Alzheimer's disease (AD), are characterized by progressive neuronal loss and cognitive decline, with tau protein aggregation serving as one of the central pathological hallmarks. This review paper explores the molecular mechanisms underlying neurodegeneration with a specific focus on tau protein hyperphosphorylation, misfolding, and aggregation into neurofibrillary tangles. It further highlights how experimental techniques such as Western blotting and immunohistochemistry (IHC) are used to investigate tau pathology in both clinical and preclinical models. Western blot analysis enables quantitative assessment of tau isoforms, phosphorylation states, and aggregation profiles, while immunohistochemistry provides spatial localization of tau deposits within brain tissues, revealing region-specific vulnerability such as the hippocampus and cortex. The study synthesizes current literature on tau-associated signaling pathways, including kinase and phosphatase dysregulation, protein clearance impairment, and neuroinflammatory contributions. Additionally, it discusses how combined application of Western blot and IHC enhances diagnostic accuracy and improves understanding of disease progression. Despite advances, challenges remain in standardization of detection methods, interpretation of tau species heterogeneity, and correlation with clinical severity. Overall, this review emphasizes that integrating biochemical and histopathological approaches provides a more comprehensive understanding of tau-driven neurodegeneration in Alzheimer's disease.

1. Introduction

The complex landscape of Alzheimer's disease (AD) is defined by a multifaceted pathophysiology that has, for decades, been interpreted through the lens of the amyloid cascade hypothesis. However, the persistent failure of amyloid-targeted therapies to significantly arrest cognitive decline has catalyzed a profound shift in focus toward the microtubule-associated protein tau (MAPT) (Garbuz et al., 2021). While the accumulation of amyloid-beta (Aβ) peptides remains a central hallmark of the disease, it is increasingly viewed as a secondary driver or an early trigger rather than the primary cause of neuronal death. The transition from physiological tau to pathological,

hyperphosphorylated aggregates is now recognized as a critical threshold in the neurodegenerative process, correlating much more robustly with synaptic loss, neuronal dysfunction, and the progression of clinical dementia (Ellis et al., 2024). Understanding the molecular mechanisms underlying tau protein aggregation requires a sophisticated integration of biochemical and morphological techniques, specifically Western blot (WB) and immunohistochemistry (IHC), which allow for the detection of tau's diverse proteoforms and their spatiotemporal evolution within the brain (Montalbano et al., 2023).

2. Pathophysiological Foundations and the Evolution of the Tau Hypothesis

The modern understanding of Alzheimer's disease began with the seminal work of Alois Alzheimer in 1907, who identified "senile plaques" and "neurofibrillary tangles" (NFTs) as the defining features of the disease (Hong et al., 2025). For nearly thirty years, the scientific community focused on the amyloid hypothesis, which posits that the imbalance between the production and clearance of amyloid-beta (Aβ)—driven by the cleavage of the amyloid precursor protein (APP) by enzymes such as gamma-secretase—leads to the formation of toxic extracellular plaques (Uddin et al., 2020). This cascade is thought to subsequently trigger neuroinflammation, oxidative stress, and tau pathology, eventually culminating in neuronal death. However, the spatial mismatch between amyloid-beta (Aβ) plaques, which are widespread across the cortex, and tau pathology, which follows a stereotypical and hierarchical progression, suggests a more nuanced relationship (Tzekaki et al., 2025).

The "Tau Hypothesis" has emerged as a compelling alternative, suggesting that the hyperphosphorylation and aggregation of tau into NFTs is the primary cause of neurodegeneration. Unlike amyloid-beta (Aβ) plaques, which can occur in individuals with no cognitive impairment, the density and distribution of NFTs are closely aligned with the severity of memory loss and cortical atrophy (Raha et al., 2022).

Table 1: Comparison of Primary Pathological Hypotheses in Alzheimer's Disease

Attribute	Amyloid Cascade Hypothesis	Tau Aggregation Hypothesis
Primary Initiator	Amyloid-beta (Aβ) peptides	Hyperphosphorylated tau protein
Genetic Basis	Mutations in APP, PSEN1, PSEN2	MAPT gene mutations and splicing
Key Lesion	Extracellular senile plaques	Intracellular neurofibrillary tangles
Anatomical Progress	Broadly cortical/neocortical early involvement	Hierarchical progression (Braak staging)
Cognitive Correlation	Moderate; often plateaus	Strong; closely tracks symptom onset
Therapeutic Target	Secretase inhibitors; anti-amyloid monoclonal antibodies	Kinase inhibitors; tau immunotherapies

3. Molecular Biology and Structural Dynamics of Tau Protein

Tau is a highly soluble, "natively unfolded" protein that belongs to the microtubule-associated protein family. In the central nervous system, it is primarily localized in the distal axons of neurons, where it binds to tubulin through its microtubule-binding domain (MBD) (Zheng et al., 2025). The primary physiological role of tau is to maintain the stability and function of the axon by promoting tubulin assembly and regulating the dynamic instability of microtubules, a process essential for the structural integrity of neurons and the efficiency of axonal transport (Li et al., 2022).

The human tau protein is encoded by the *mapt* gene on chromosome 17.

Through alternative splicing of exons 2, 3, and 10, six major isoforms are generated in the adult human brain. These isoforms vary based on the number of N-terminal inserts (0N, 1N, or 2N) and the number of highly conserved repeat regions in the MBD (3R or 4R) (An et al., 2022). The 4R tau isoforms, which include the residues encoded by exon 10, exhibit a higher affinity for microtubules and are more efficient at promoting their assembly compared to 3R isoforms. Under normal physiological conditions, the ratio of 3R to 4R tau is approximately equal, but an imbalance in this ratio is often associated with the development of tauopathies, including specific forms of frontotemporal dementia and Alzheimer's disease (Chen et al., 2025).

4. Molecular Mechanisms of Tau Aggregation: The Role of Post-Translational Modifications

In Alzheimer's disease, tau undergoes a pathological transformation characterized by its dissociation from microtubules and its subsequent self-assembly into insoluble filaments. This process is driven by an array of post-translational modifications (PTMs) that alter tau's charge, conformation, and stability (Wang et al., 2023).

Figure 1. Cellular and molecular pathways of neuroinflammation, protein aggregation, and blood-brain barrier dysfunction in the central nervous system.



4.1 Hyperphosphorylation: The Primary Driver of Tau Dysfunction

Phosphorylation is the most extensively studied PTM of tau, occurring primarily at serine (S), threonine (T), and tyrosine (Y) residues. Under normal conditions, only 2-3 phosphate groups are present per molecule, whereas in the AD brain, tau levels reach up to 8 phosphate groups per molecule (Basurto-Islas et al., 2025). Hyperphosphorylation at critical sites—such as Ser262, Ser293, Ser324, and Ser356 within the MBD—markedly reduces tau's affinity for microtubules, leading to their destabilization and the failure of axonal transport (Yan et al., 2023).

The dephosphorylation of tau is mediated by the protein phosphatase (PP) family, where PP2A accounts for approximately 70% of activity in the human brain. In Alzheimer's patients, PP2A activity is reduced by 20-40%, leaving kinases unchecked and promoting paired helical filaments (PHFs) (Islam et al., 2025).

4.2 Acetylation and Truncation as Catalysts for Aggregation

Acetylation of lysine residues at sites like Lys280 and Lys281 has been specifically detected in AD brain tissue. This modification prevents ubiquitin-mediated degradation of tau, leading to its accumulation and pathological spreading. Truncation of the tau protein by proteases such as caspases and calpains also plays a major role; fragments truncated at Glu391 or Asp421 are highly aggregate-prone and often serve as the core for PHF assembly (Wen et al., 2025).

Table 2: Impact of Significant Post-Translational Modifications on Tau in Alzheimer's Disease

PTM Type	Mechanism/Sites	Impact on Tau in AD
Methylation	Mono- and dimethylation at 11 sites	Potentially protective; can attenuate nucleation.
SUMOylation	Conjugation of SUMO1 at Lys340	Suppresses degradation and promotes phosphorylation.
Ubiquitination	Covalent modification for degradation	Disrupted by acetylation; leads to aggregate build-up.
Glycation	Interaction with sugars	Promotes cross-linking and insolubility.

5. The Prion-Like Spreading and Seed-Dependent Aggregation

Recent evidence has established that tau pathology spreads through the brain in a "prion-like" manner. Pathogenic, misfolded tau proteins—often in the form of soluble oligomers—can be released from one neuron and internalized by another via heparin sulfate proteoglycans (HSPGs) and specific receptors such as muscarinic or AMPA receptors. Once inside the recipient cell, these "seeds" recruit soluble endogenous tau into larger, aberrant conformations, a process known as seed-dependent aggregation (Di Spiezio et al., 2021).

6. Biochemical Analysis of Tau Protein Using Western Blot

Western blot (WB) is indispensable for characterizing tau's molecular weight, isoform distribution, and solubility profiles. In AD research, the differentiation between soluble, physiological tau and insoluble aggregates is critical (Liu et al., 2026).

6.1 Methodology: Sarkosyl-Insoluble Fractions and Diagnostic Banding

Biochemical analysis typically involves extracting the sarkosyl-insoluble fraction from brain tissue. In Alzheimer's disease, immunoblot analysis reveals a characteristic triplet of bands at approximately 60, 64, and 68 kDa, representing the hyperphosphorylated forms of all six isoforms. This pattern is diagnostic; for instance, Pick's Disease primarily displays 3R tau at 60 and 64 kDa, while PSP and CBD display 4R tau at 64 and 68 kDa (Henríquez et al., 2020).

6.2 Antibody Specificity and Validation Challenges

The accuracy of WB is contingent upon antibody specificity. Validation of over 50 commercial antibodies has revealed that some "total" tau antibodies, like the Tau-5 clone, are partially inhibited by phosphorylation, potentially missing pathologically relevant species. Furthermore, the "oligomer-specific" antibody T22 has been found to react with monomeric tau on WB, raising questions about previous quantification data (Yang et al., 2025)

Figure 1 Comprehensive Strategies and Methodological Frameworks for



7. Morphological Analysis of Tau Pathology Using Immunohistochemistry

Immunohistochemistry (IHC) offers spatial resolution, allowing visualization of the cellular and regional distribution of aggregates. It is the standard tool for determining Braak stages, which describe the topographical expansion of the disease (Suloh et al., 2025).

7.1 The Braak Staging System and the AT8 Antibody

The staging of neurofibrillary pathology is based on the progressive involvement of brain regions using the AT8 antibody, which targets the pS202/T205 phospho-epitope (Joseph et al., 2020).

Table 3: The Braak Staging System for Neurofibrillary Pathology

Braak Stage	Anatomical Region Involved	Clinical Significance
Stage I	Transentorhinal region (first cortical site)	Preclinical; often asymptomatic.
Stage II	Entorhinal region and CA1 of hippocampus	Subtle memory deficits may emerge.
Stage III	Severe involvement of hippocampus and amygdala	Intermediate stage; early clinical dementia.
Stage IV	Medial and superior temporal gyri	Significant cognitive impairment.
Stage V	Neocortical association areas	Advanced dementia.
Stage VI	Primary sensory and motor areas (striate area)	End-stage AD.

7.2 Morphology of Tangles and Threads in IHC

IHC identifies several tau-positive structures:

- **Pretangles:** Diffuse granular staining in the neuronal soma.
- **Neurofibrillary Tangles (NFTs):** Large, compact intracellular aggregates.
- **Neuropil Threads (NTs):** Filaments found in axons and dendrites.
- **Extracellular (Ghost) Tangles:** Remnants of dead neurons consisting of the PHF core (Hassan et al., 2022).

8. Synergy Between Biochemical and Morphological Techniques

The most comprehensive understanding comes from integrating WB and IHC. While WB quantifies total protein and truncation, IHC provides anatomical context. Integrated studies have revealed a significant spatiotemporal mismatch: amyloid-beta

42 (Aβ42) aggregation is widespread early on, while tau pathology progresses hierarchically, suggesting that APP dysfunction facilitates the neuron-to-neuron propagation of tau (Zhang et al., 2022).

9. Future Directions: Spatial Omics and Artificial Intelligence

As the field moves toward 2026, focus is shifting toward higher-resolution techniques and automated diagnostics (Liu et al., 2024).

9.1 Spatial Single-Cell Proteomics

By combining laser microdissection with mass spectrometry, researchers have analyzed individual tangle-positive neurons. This has shown that the transition to NFT is a continuum of proteomic changes rather than a discrete jump, involving early remodeling of proteostasis networks followed by disruption of synaptic pathways (Singh et al., 2025).

9.2 AI-Assisted Automated Staging

Artificial intelligence is revolutionizing digital neuropathology. CNN-based models evaluated in 2025 can automatically stage tau pathology in AT8-stained micrographs by capturing multi-scale spatial representations and texture patterns overlooked by human observers (Sun et al., 2025).

10. Therapeutic Strategies and Tau-Targeting Trials

Current research focuses on:

1. **Kinase Inhibition:** Targeting glycogen synthase kinase 3 beta (GSK3β) or cyclin-dependent kinase 5 (CDK5).
2. **Aggregation Inhibition:** Small molecules designed to reduce the thermodynamic stability of tau fibers.
3. **Tau Immunotherapies:** Monoclonal antibodies like BMS-986446, which target the microtubule-binding region (R1-R3) to prevent spread, received FDA Fast Track designation in 2025 (van der Gaag et al., 2024).

Conclusion

In conclusion, tau protein aggregation plays a fundamental role in the molecular pathology of Alzheimer's disease and represents a key driver of neurodegeneration. Abnormal phosphorylation and misfolding of tau disrupt neuronal stability and lead to the formation of neurofibrillary tangles, which correlate strongly with disease progression and cognitive decline. Techniques such as Western blotting and immunohistochemistry are essential for elucidating these pathological changes, as they provide complementary biochemical and structural insights into tau expression, modification, and distribution in brain tissues. While Western blot offers quantitative evaluation of tau species and post-translational modifications, immunohistochemistry enables precise localization of pathological aggregates within affected brain regions. However, variability in experimental protocols and limitations in detecting early-stage tau changes remain significant challenges. Future research should focus on improving detection sensitivity, developing standardized analytical frameworks, and integrating multi-modal approaches to better understand tau pathology. Such advancements will be crucial for developing targeted therapeutic strategies aimed at slowing or preventing Alzheimer's disease progression.

REFERENCES

Basurto-Islas, G., Diaz, M. C., Ocampo, L. M. Z., Martínez-Herrera, M., & López-Camacho, P. Y. (2025). Natural products against tau hyperphosphorylation-induced aggregates: Potential therapies for Alzheimer's disease. *Archiv der Pharmazie*, *358*(1), e2400721.

Yan, M., Tang, L., Dai, L., Lei, C., Xiong, M., Zhang, X., ... & Zhang, Z. (2023). Cofilin promotes tau pathology in Alzheimer's disease. *Cell Reports*, *42*(2).

Islam, M. R., Rauf, A., Akter, S., Akter, H., Al-Imran, M. I. K., Islam, S., ... & Iriti, M. (2025). Epigallocatechin 3-gallate-induced neuroprotection in neurodegenerative diseases: molecular mechanisms and clinical insights. *Molecular and Cellular Biochemistry*, *480*(6), 3363-3383.

Wen, T., Meng, L., Liu, H., Zhang, Q., Dai, L., Huang, L., ... & Zhang, Z. (2025). Fibrinogen-tau Aggregates Exacerbate Tau Pathology and Memory Deficits in Alzheimer's Disease Model Mice: T. Wen et al.: Fibrinogen-tau Aggregates Worsen Alzheimer's Disease. *Neuroscience Bulletin*, *41*(7), 1246-1260.

Di Spiezio, A., Marques, A. R., Schmidt, L., Thießen, N., Gallwitz, L., Fogh, J., ... & Saftig, P. (2021). Analysis of cathepsin B and cathepsin L treatment to clear toxic lysosomal protein aggregates in neuronal ceroid lipofuscinosis. *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease*, *1867*(10), 166205.

Garbuz, D. G., Zatsepina, O. G., & Evgen'ev, M. B. (2021). Beta amyloid, tau protein, and neuroinflammation: an attempt to integrate different hypotheses of Alzheimer's disease pathogenesis. *Molecular Biology*, *55*(5), 670-682.

Ellis, M. J., Lekka, C., Holden, K. L., Tulmin, H., Seedat, F., O'Brien, D. P., ... & Stefana, M. I. (2024). Identification of high-performing antibodies for the reliable detection of Tau proteoforms by Western blotting and immunohistochemistry. *Acta Neuropathologica*, *147*(1), 87.

Hong, X., Huang, L., Lei, F., Li, T., Luo, Y., Zeng, M., & Wang, Z. (2025). The role and pathogenesis of Tau protein in Alzheimer's disease. *Biomolecules*, *15*(6), 824.

Uddin, M. S., Tewari, D., Sharma, G., Kabir, M. T., Barreto, G. E., Bin-Jumah, M. N., ... & Ashraf, G. M. (2020). Molecular Mechanisms of ER Stress and UPR in the Pathogenesis of Alzheimer's Disease. *Molecular neurobiology*, *57*(7), 2902-2919.

Li, L., Jiang, Y., Wu, G., Mahaman, Y. A. R., Ke, D., Wang, Q., ... & Wang, X. (2022). Phosphorylation of truncated tau promotes abnormal native tau pathology and neurodegeneration. *Molecular Neurobiology*, *59*(10), 6183-6199.

An, F., Bai, Y., Xuan, X., Bian, M., Zhang, G., & Wei, C. (2022). 1, 8-Cineole ameliorates advanced glycation end products-induced Alzheimer's disease-like pathology in vitro and in vivo. *Molecules*, *27*(12), 3913.

Chen, G., Wang, M., Zhang, Z., Hong, D. K., Ahn, E. H., Liu, X., ... & Ye, K. (2025). ApoE3 R136S binds to Tau and blocks its propagation, suppressing neurodegeneration in mice with Alzheimer's disease. *Neuron*, *113*(5), 719-736.

Liu, B., Zhao, Q., Shi, Q., Xu, W., Shi, F., Yang, R., & Zhou, X. (2026). Hypothermia Alleviates TBI-Induced Tau Hyperphosphorylation Through RBM3-Dependent GSK-3β and AMPK Pathways: B. Liu et al. *Neurocritical Care*, *44*(1), 72-84.

Henríquez, G., Gomez, A., Guerrero, E., & Narayan, M. (2020). Potential role of natural polyphenols against protein aggregation toxicity: in vitro, in vivo, and clinical studies. *ACS Chemical Neuroscience*, *11*(19), 2915-2934.

Yang, Y., Xu, A., Xie, P., & Yang, J. (2025). Molecular Mechanism of Dexmedetomidine in Alzheimer's Disease: Machine Learning Identifies RGS7 as a Key Therapeutic Targe. *Chemical Biology & Drug Design*, *106*(5), e70185.

Suloh, H., Ojha, S. K., Kartawy, M., Hamoudi, W., Tripathi, M. K., Bazbaz, W., ... & Amal, H. (2025). Shared early molecular mechanisms revealed in P301S and 5xFAD Alzheimer's disease mouse models. *Translational Psychiatry*, *15*(1), 97.

Joseph, C., Mangani, A. S., Gupta, V., Chitranshi, N., Shen, T., Dheer, Y., ... & Gupta, V. (2020). Cell cycle deficits in neurodegenerative disorders: uncovering molecular mechanisms to drive innovative therapeutic development. *Aging and disease*, *11*(4), 946.

Hassan, H. M., Elnagar, M. R., Abdelrazik, E., Mahdi, M. R., Hamza, E., Elattar, E. M., ... & ELdesoqui, M. (2022). Neuroprotective effect of naringin against cerebellar changes in Alzheimer's disease through modulation of autophagy, oxidative stress and tau expression: An experimental study. *Frontiers in neuroanatomy*, *16*, 1012422.

Zhang, G., Meng, L., Wang, Z., Peng, Q., Chen, G., Xiong, J., & Zhang, Z. (2022). Islet amyloid polypeptide cross-seeds tau and drives the neurofibrillary pathology in Alzheimer's disease. *Molecular Neurodegeneration*, *17*(1), 12.

Liu, C., Meng, L., Gao, Y., Chen, J., Zhu, M., Xiong, M., ... & Zhang, Z. (2024). PM2. 5 triggers tau aggregation in a mouse model of tauopathy. *JCI insight*, *9*(14), e176703.

Singh, A., Singh, L., & Dalal, D. (2025). Neuroprotective potential of Hispidulin and diosmin: a review of molecular mechanisms. *Metabolic Brain Disease*, *40*(5), 188.

Sun, C., Gao, X., Sha, S., Wang, S., Shan, Y., Li, L., ... & Du, H. (2025). Berberine alleviates Alzheimer's disease by activating autophagy and inhibiting ferroptosis through the JNK-p38MAPK signaling pathway. *International immunopharmacology*, *155*, 114550.

van der Gaag, B. L., Deshayes, N. A., Breve, J. J., Bol, J. G., Jonker, A. J., Hoozemans, J. J., ... & van de Berg, W. D. (2024). Distinct tau and alpha-synuclein molecular signatures in Alzheimer's disease with and without Lewy bodies and Parkinson's disease with dementia. *Acta Neuropathologica*, *147*(1), 14.

Montalbano, M., Majmundar, L., Sengupta, U., Fung, L., & Kayed, R. (2023). Pathological tau signatures and nuclear alterations in neurons, astrocytes and microglia in Alzheimer's disease, progressive supranuclear palsy, and dementia with Lewy bodies. *Brain Pathology*, *33*(1), e13112.

Tzekaki, E., Bekiari, C., Pantazaki, A., Tsantarliotou, M., Tsolaki, M., & Lavrentiadou, S. N. (2025). A new protocol for the development of organoids based on molecular mechanisms in the developing newborn rat brain: Prospective applications in the study of Alzheimer's disease. *Journal of Neuroscience Methods*, *417*, 110404.

Raha, A. A., Biswas, A., Henderson, J., Chakraborty, S., Holland, A., Friedland, R. P., ... & Raha-Chowdhury, R. (2022). Interplay of ferritin accumulation and ferroportin loss in ageing brain: implication for protein aggregation in down syndrome dementia, Alzheimer's, and Parkinson's diseases. *International journal of molecular sciences*, *23*(3), 1060.

Zheng, X., Luo, Z., Zheng, J., Deng, C., Liu, D., Chen, Y., ... & Song, J. X. (2025). Electroacupuncture Attenuates High-Fat Diet-Exacerbated Alzheimer's Pathology by Enhancing TFEB/TFE3-Mediated Autophagic Clearance of Tau and NLRP3 Inflammasome in 3xTg Mice. *CNS Neuroscience & Therapeutics*, *31*(7), e70497.

Wang, C., Chang, Y., Zhu, J., Wu, Y., Jiang, X., Zheng, S., ... & Ma, R. (2023). AdipoRon mitigates tau pathology and restores mitochondrial dynamics via AMPK-related pathway in a mouse model of Alzheimer's disease. *Experimental Neurology*, *363*, 114355.